Deutsche Bank AG Reduces Position in Evolus, Inc. (NASDAQ:EOLS)

Deutsche Bank AG reduced its holdings in shares of Evolus, Inc. (NASDAQ:EOLSFree Report) by 43.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 307,769 shares of the company’s stock after selling 237,820 shares during the period. Deutsche Bank AG’s holdings in Evolus were worth $3,398,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Tri Locum Partners LP purchased a new stake in shares of Evolus in the fourth quarter valued at about $8,198,000. Gilder Gagnon Howe & Co. LLC raised its holdings in Evolus by 287.2% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company’s stock valued at $7,753,000 after acquiring an additional 520,859 shares in the last quarter. Caligan Partners LP grew its position in shares of Evolus by 22.7% during the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock valued at $29,724,000 after buying an additional 498,900 shares during the last quarter. Allostery Investments LP bought a new position in shares of Evolus in the fourth quarter valued at approximately $4,760,000. Finally, Altium Capital Management LLC boosted its holdings in Evolus by 93.0% during the fourth quarter. Altium Capital Management LLC now owns 685,000 shares of the company’s stock worth $7,562,000 after buying an additional 330,000 shares in the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

EOLS has been the topic of a number of recent research reports. BTIG Research started coverage on shares of Evolus in a report on Thursday, April 17th. They set a “buy” rating and a $21.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Evolus in a report on Thursday, May 8th. Barclays raised their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Evolus in a research report on Thursday, April 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Evolus presently has an average rating of “Buy” and a consensus price target of $23.75.

Read Our Latest Report on Evolus

Insider Buying and Selling

In related news, insider David Moatazedi sold 15,787 shares of the company’s stock in a transaction on Monday, May 12th. The stock was sold at an average price of $9.87, for a total transaction of $155,817.69. Following the completion of the sale, the insider now directly owns 492,832 shares in the company, valued at $4,864,251.84. This represents a 3.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Rui Avelar sold 27,904 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $370,007.04. Following the completion of the sale, the insider now owns 362,467 shares of the company’s stock, valued at approximately $4,806,312.42. This trade represents a 7.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 86,241 shares of company stock worth $1,048,666. 5.90% of the stock is owned by corporate insiders.

Evolus Stock Performance

Shares of EOLS stock opened at $9.96 on Wednesday. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The firm has a market capitalization of $642.18 million, a price-to-earnings ratio of -10.94 and a beta of 1.11. The stock has a fifty day moving average of $11.19 and a 200 day moving average of $12.24. Evolus, Inc. has a 52 week low of $8.67 and a 52 week high of $17.82.

Evolus Company Profile

(Free Report)

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Further Reading

Want to see what other hedge funds are holding EOLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolus, Inc. (NASDAQ:EOLSFree Report).

Institutional Ownership by Quarter for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.